



Hepatic LOX-1 Downregulation Is Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease Improvement in High-Fat Diet-Fed Rats: Protective Role of Aerobic Exercise

Simin Riahy ¹, Gholamreza Hamidian ², Hasan Hadi Al-Ziyadi ³, Nader Hamedchaman ^{4,*}

¹ Clinical Biomechanics and Ergonomics Center, Aja University of Medical Sciences, Tehran, Iran

² Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran

³ Department of Exercise Physiology, Faculty of Sports Sciences, Muthanna University, Samawah, Iraq

⁴ Department of Exercise Physiology, Faculty of Sports Sciences, Shomal University, Amol, Iran

*Corresponding Author: Department of Exercise Physiology, Faculty of Sports Sciences, Shomal University, Amol, Iran. Email: nader.hamedchaman@gmail.com

Received: 28 December, 2025; Revised: 19 June, 2026; Accepted: 17 July, 2026

Abstract

Background: Changes in dietary composition and increased dietary fat intake contribute to hypertriglyceridemia and subsequent dyslipidemia, thereby exacerbating chronic, progressive metaflammatory conditions. These effects are mediated by impaired triglyceride clearance and reduced lipolytic enzyme activity, ultimately leading to deterioration of liver function and metabolic dysfunction-associated steatotic liver disease (MASLD).

Objectives: This study aimed to investigate how moderate-intensity swimming exercise modulates high-fat diet-induced structural changes and metaflammation in the liver, with a particular focus on the role of the lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1).

Methods: Thirty-two male Wistar rats were randomly allocated to four groups ($n = 8/\text{group}$): Control (standard diet, sedentary), *Exercise* (standard diet plus exercise), high-fat diet (HFD; high-fat diet, sedentary), and *Exercise plus HFD* (high-fat diet plus exercise). Rats in the exercise groups swam freely for 1 hour/day, 5 days/week, for 8 weeks. Approximately 48 hours after completion of the training protocol, blood samples were collected to assess the lipid profile, glucose, and nitrogen oxides (NOx). Liver tissue was also isolated and evaluated using histological and immunohistochemical methods.

Results: Chronic HFD consumption significantly increased body weight, serum cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), glucose, and NOx levels, as well as tissue LOX-1 and interleukin 6 (IL-6) levels, and distorted histopathological characteristics compared with the Control group ($P < 0.001$). Aerobic swimming training significantly reversed HFD-induced weight gain and lipid profile upregulation and modulated oxidative stress by downregulating hepatic LOX-1 levels ($P < 0.05$), which was associated with reduced IL-6 protein expression and improved histological features.

Conclusions: Chronic moderate aerobic exercise may protect against HFD-induced MASLD by reducing inflammatory stress and is associated with the suppression of MASLD development. These findings identify LOX-1 as a potential biomarker and suggest that exercise-mediated LOX-1 downregulation may represent a therapeutic target; however, further mechanistic studies are needed to establish causality.

Keywords: Metaflammation, High-fat Diet, Aerobic Exercise, Swimming, LOX-1

1. Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a predominant cause of chronic liver disease worldwide, affecting approximately 30% of the global adult population.

Characterized by hepatic steatosis in the absence of significant alcohol consumption, MASLD encompasses a spectrum ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), which may progress to cirrhosis and hepatocellular carcinoma (1). The rising prevalence of MASLD parallels the global

Copyright © 2026, Riahy et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (<https://creativecommons.org/licenses/by/4.0/>), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

How to Cite: Riahy S, Hamidian G, Hadi Al-Ziyadi H, Hamedchaman N. Hepatic LOX-1 Downregulation Is Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease Improvement in High-Fat Diet-Fed Rats: Protective Role of Aerobic Exercise. *Hepat Mon.* 2026;26(1):e169226. doi: <https://doi.org/10.5812/hepatmon-169226>

epidemic of obesity and type 2 diabetes mellitus, positioning it as a major public health burden with hepatic and extrahepatic consequences, including cardiovascular disease, chronic kidney disease, and various malignancies (2-4).

The pathogenesis of MASLD is multifactorial, involving complex interactions among dietary factors, metabolic dysregulation, and inflammatory pathways. Overnutrition from high-carbohydrate and high-fat diets promotes abnormal fat storage, lipotoxicity, and increased de novo lipogenesis in hepatocytes, thereby driving disease initiation and progression (1, 5). Insulin resistance, a hallmark of MASLD, exacerbates hepatic lipid accumulation and is closely associated with elevated serum oxidized low-density lipoprotein (oxLDL) levels, which contribute to lipotoxicity and cellular injury (2, 3). The inflammatory milieu characteristic of MASLD is sustained by proinflammatory cytokines and adipose tissue-derived mediators, creating a state of chronic low-grade inflammation, termed metaflammation, that perpetuates hepatocellular damage and fibrosis (4, 6).

Among the inflammatory mediators implicated in MASLD pathophysiology, interleukin 6 (IL-6) plays a central role. Elevated IL-6 levels in patients with MASLD correlate with hepatic inflammation, fibrosis, and insulin resistance, suggesting its involvement in disease progression (7, 8). IL-6 orchestrates lipid homeostasis and systemic metabolic responses, fostering dynamic interactions that influence MASLD severity and clinical outcomes (8). Concurrently, oxidative and nitrosative stress, reflected by increased levels of nitric oxide derivatives (NOx), contribute to hepatocellular injury through protein nitration, mitochondrial dysfunction, and impaired metabolic homeostasis (9). Reactive nitrogen and oxygen species promote lipid peroxidation, generating oxidized LDL that binds to lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) (10).

LOX-1, a multiligand scavenger receptor primarily expressed in vascular endothelial cells, macrophages, and fibroblasts, is activated by diverse stimuli, including proinflammatory cytokines (IL-1 β , IL-6, and TNF- α), oxidized LDL, angiotensin II, and shear stress (11, 12). Although LOX-1 expression remains low under physiological conditions, it is markedly upregulated during oxidative stress and inflammatory responses, conditions that are prevalent in MASLD (13, 14). Activation of LOX-1 triggers downstream signaling cascades that promote endothelial dysfunction, apoptosis, and additional inflammatory cytokine production, establishing a feed-forward loop that

amplifies tissue injury (15). Emerging evidence from gene knockout studies implicates LOX-1 in the pathogenesis of MASH, although its precise role in exercise-mediated hepatic protection remains incompletely defined (13).

Given the limited pharmacological options for MASLD management, nonpharmacological interventions, particularly physical activity, have gained attention as cornerstone therapeutic strategies. Aerobic exercise exerts pleiotropic effects that counter metabolic dysfunction, including improved insulin sensitivity, enhanced mitochondrial biogenesis and function, reduced systemic inflammation, favorable modulation of lipid profiles, and increased antioxidant capacity (16, 17). Exercise-induced shear stress and associated hemodynamic changes may further enhance endothelial nitric oxide bioavailability and upregulate antioxidant enzyme systems, contributing to lipolytic and anti-inflammatory effects (17, 18). Moderate-intensity aerobic training has also been shown to reduce serum glucose, malondialdehyde, insulin resistance, and myocardial LOX-1 expression in diabetic rat models (10).

2. Objectives

Despite accumulating evidence linking exercise to improved metabolic homeostasis, the specific effects of chronic swimming exercise on hepatic LOX-1 expression and its relationship to MASLD pathophysiology remain incompletely characterized. This study was designed to investigate the association between moderate-intensity aerobic swimming exercise and hepatic LOX-1 expression in a high-fat diet-induced rat model of MASLD.

3. Methods

3.1. Animals

This experimental study included 32 male Wistar rats aged 6 to 8 weeks and weighing 200 ± 20 g, obtained from the Pasteur Institute Laboratory. Rats were housed in standard polyester cages (4 rats per cage) under controlled conditions ($55 \pm 5\%$ humidity, $22 \pm 2^\circ\text{C}$, 12-hour light/dark cycle) to ensure consistent environmental conditions. They had ad libitum access to high-fat pellets and/or a standard chow diet, according to the dietary interventions. All procedures complied with NIH regulations for animal care and were approved by the Ethics Committee of AJA University of Medical Sciences (IR.AJAUMS.REC.1399.256).

3.2. Experimental Design

After 1 week of acclimatization to the laboratory environment and swimming pool (110 × 100 × 80 cm, approximately 30°C), the rats were divided into the HFD (n = 16) and normal control (NC; n = 16) groups (phase I). During phase I (4 weeks), rats had free access to standard pellets and tap water (normal control group) or an HFD. The HFD pellets used for the HFD group were formulated by supplementing standard rodent chow with 2% cholesterol powder (Germany, Merck) and 60% animal fat. The fat composition comprised 71% monounsaturated, 23% trans-monounsaturated, and 6% polyunsaturated fat ingredients, as presented in Table 1 (13, 15). After 4 weeks, rats in the HFD group were randomly assigned to 2 equal groups for phase II (8 weeks): 1) HFD: rats received an HFD and remained sedentary; and 2) *Exercise plus* HFD (Exe + HFD): rats received an HFD and undertook an 8-week exercise program. The control rats were also divided into 2 equal groups: 3) Control: rats were maintained on a standard diet and kept sedentary; and 4) *Exercise* (Exe): rats received a standard diet and underwent an 8-week exercise regimen (Figure 1).

3.3. Aerobic Swimming Training Protocol and Load Measurements

Load-free swimming exercise was used as a model of moderate aerobic training. To ensure safe adaptation, rats initially completed a 10-minute swimming session to minimize stress and fatigue before the formal program. After this introductory period, rats swam freely at moderate intensity, with the daily duration increased by 10 minutes/day until it reached 60 minutes by the end of the second week. This protocol was then continued for 1 hour/day, 5 days/week, for 8 weeks.

For the inactive groups (Control and HFD), animals were placed in a low, shallow tank in which their paws touched the bottom while their heads remained above water. This procedure provided similar environmental exposure without actual swimming. To ensure animal safety and comfort, animals were thoroughly dried and placed in a warm chamber after each swim session to prevent hypothermia.

3.4. Tissue Extraction and Blood Collection

At the beginning and end of the experimental protocol, body weights were recorded using a digital scale. Forty-eight hours after the final exercise session and after a 12-hour fast, blood samples were collected via heart puncture and centrifuged at 2500 rpm for 15

minutes at 4°C to separate plasma, which was then stored at -20°C for biochemical analysis. Liver tissue was removed and embedded in formalin-fixed paraffin-embedded blocks for immunohistochemistry, and another portion was fixed for histological assessment.

3.5. Nitric Oxide Assay

Plasma levels of nitric oxide metabolites (NOx) were determined using the Griess colorimetric reaction. Plasma proteins were removed by deproteinizing 0.5 mL of plasma with 0.1 mL of zinc sulfate. The mixture was centrifuged for 20 minutes at 4°C and 4000 rpm, and the clear supernatant was collected for analysis. Nitrite was produced by reacting 0.1 mL of nitrate with 0.1 mL of vanadium (III) chloride, 0.05 mL of 0.01% sulfanilamide, and 0.05 mL of N-(1-naphthyl) ethylenediamine. Absorbance was measured spectrophotometrically, and NOx concentrations were calculated according to the standard curve.

3.6. Immunohistochemistry Assay

The expression of LOX-1 receptors and IL-6 proteins was evaluated using immunohistochemistry. For LOX-1, tissue sections were incubated with goat-derived anti-rabbit LOX-1 conjugated with FITC (ab5926; RRID: AB_920795) at a dilution of 1:1000. IL-6 protein levels were assessed using a specific anti-IL-6 antibody (ab9324; RRID: AB_307178). After antibody incubation, hematoxylin was used as a counterstain to delineate cellular structures. Protein expression was quantified by determining the percentage of the area exhibiting positive staining using ImageJ software (9, 10).

3.7. Histological Changes

After washing the liver in physiological saline, the tissue was fixed in 4% paraformaldehyde for approximately 48 hours. It was then dehydrated through a graded alcohol series, cleared with xylene solution, and embedded in liquid paraffin blocks. The tissue was cut into 5-μm sections using a microtome and placed on slides. To evaluate morphological changes, hematoxylin and eosin staining was performed, and the sections were examined under a light microscope.


3.8. Statistical Analysis

SPSS version 22 was used for statistical analyses. Intergroup differences were compared using 1-way ANOVA followed by the Tukey post hoc test, with significance set at $P < 0.05$.

4. Results

Table 1. Nutritional Composition of the Diets^a

Components	Normal Diet		High-fat Diet	
	g	kcal	g	kcal
Kcal/g	-	3.71	-	5.05
Carbohydrates	60	64.4	35.7	28.2
Protein	23.1	24.8	20	16
Total fat	4.3	10.4	31.4	62.1
Fat ingredients				
Saturated fatty acids	37.3		62.69 ^b	

^a Values are expressed as percentage.^b Structured fatty acids include: monounsaturated (71.62%), trans monounsaturated (23.12%) and polyunsaturated (5.21%).**Figure 1.** Study design of the study

4.1. Effects of High-Fat Diet and Exercise on Body Weight

After 8 weeks of HFD consumption, the HFD group had a higher final body weight than the Control, Exercise, and Exercise plus HFD groups, and these differences were statistically significant ($P < 0.05$). These findings underscore the effect of diet on body weight management.

4.2. Effects of High-Fat Diet and Exercise on Serum Glucose and Lipid Profile

Eight weeks of HFD significantly altered the lipid profile. The HFD group exhibited elevated cholesterol levels compared with the Control group ($P < 0.01$). However, the exercise intervention did not significantly reduce serum cholesterol levels, as the Exercise plus HFD group maintained similarly elevated cholesterol levels compared with the HFD group ($P > 0.05$). Additionally, triglyceride levels were markedly higher in the HFD group than in the Control group ($P < 0.01$). Conversely, 8 weeks of exercise significantly reduced triglyceride levels in the Exercise plus HFD group compared with the HFD group ($P < 0.05$). Exercise did not significantly alter LDL-C levels, as no significant difference was observed.

Table 2. Effects of High-Fat Diet and Exercise on Body Weight, Serum Lipid Profile, Glucose, and NOx Levels^a

Groups	Control	Exercise	High-Fat Diet	Exercise + High-Fat Diet	P-Value
Initial body weight (g)	194 ± 7	205 ± 3	224 ± 38	228 ± 14	0.78
Final body weight (g)	324.4 ± 41	348.6 ± 28	394 ± 29 ^{b, c, d}	352.4 ± 23	0.037
Gonadosomatic index (%)	1.49 ± 0.09	1.55 ± 0.10	1.20 ± 0.15 ^{b, c, d}	1.40 ± 0.12	0.044
Cholesterol (mg/dL)	79.6 ± 20	97.6 ± 28	164.5 ± 50 ^{b, c}	223 ± 64 ^{ab}	0.001
Triglyceride (mg/dL)	90.8 ± 17	84.6 ± 20	169.6 ± 47 ^{b, c, d}	154 ± 40	0.001
LDL-C (mg/dL)	65.73 ± 3	50.7 ± 7	157.2 ± 43 ^{ab}	168.7 ± 56 ^{ab}	0.029
Glucose (mg/dL)	124 ± 23	111.33 ± 22	141.5 ± 22 ^{b, c}	144 ± 25	0.55
NOx (μmol/L)	3.7 ± 0.02	5.1 ± 1.3	6.1 ± 1.8 ^{b, c, d}	4.6 ± 0.7	0.041

^a Values are expressed as mean ± SD. Abbreviations: LDL-C, low-density lipoprotein cholesterol; NOx, nitrogen oxides.

^b Versus the Control group.

^c versus the Exercise group.

^d versus the High-Fat Diet and Exercise plus High-Fat Diet group.




Figure 2. Protein levels of LOX1 in liver tissue. Brown color in the context is the sign of LOX1 protein expression. The images are magnified at 200 X and 400 X with a scale bar set at 200μm. The data are presented as the mean ± standard deviation (SD). The groups are labeled as: Exe: Exercise, HFD: High fat diet group. Significant differences are denoted as *** $P < 0.001$ for the HFD group when compared to the Cont, Exe, and HFD + Exe groups, and *** $P < 0.001$ for the HFD + Exe group versus the Cont and Exe groups

between the HFD and *Exercise plus* HFD groups ($P > 0.05$). Glucose levels increased slightly with the high-fat diet, and exercise did not significantly affect this variable (Table 2).

4.3. Effects of High-Fat Diet and Exercise on Serum Nitric Oxide

After 8 weeks on an HFD, the HFD group showed a significant elevation in serum NOx levels compared with the Control group ($P < 0.05$). The exercise

intervention reduced NOx levels in the *Exercise plus* HFD group compared with the HFD group, supporting the potential of lifestyle modification to mitigate diet-related oxidative and nitrosative changes.

4.4. Immunohistochemical Analysis of Hepatic IL-6 and LOX-1 Protein Expression

Immunohistochemical analysis of hepatic expression of the proinflammatory cytokine IL-6 and the oxidative stress receptor LOX-1 revealed distinct group-specific




Figure 3. Protein levels of IL-6 in liver tissue. The data are presented as the mean $\pm$ standard deviation (SD). Brown color in the tissue is the sign of IL-6 protein expression. Images were captured at magnifications of 200 X and 400 X, with a scale bar representing 200 μ m. The groups are labeled as: HFD: High fat diet. Statistical significance is denoted as: *** $P < 0.001$ for comparisons between the HFD group and the Cont, Exe, and HFD + Exe groups. Also, *** $P < 0.001$ for the HFD + Exe group when compared to the Cont and Exe groups.

patterns. Minimal immunoreactivity for both targets was observed in the Control and *Exercise* groups, indicating low basal expression under standard conditions and confirming that aerobic exercise alone did not induce inflammatory or oxidative stress signaling in hepatic tissue (Figures 2 and 3)

Concurrent implementation of the 8-week aerobic exercise intervention in the *Exercise plus* HFD group significantly attenuated this diet-induced upregulation, resulting in a marked reduction in immunostaining intensity for both IL-6 and LOX-1 relative to the sedentary HFD group ($P < 0.01$). These observations highlight the potential of exercise to attenuate hepatic inflammation and oxidative stress pathways associated with metabolic dysfunction. Nevertheless, despite this exercise-mediated reduction, IL-6 and LOX-1 expression levels in the *Exercise plus* HFD group remained higher than those in the Control group, suggesting partial rather than complete normalization of hepatic inflammatory and oxidative responses.

4.5. Histopathological Analyses

Histopathological evaluation revealed preserved hepatic architecture in the Control and *Exercise* groups, with normal hepatocyte morphology and no evidence of steatosis or inflammatory infiltration. In contrast, the

HFD group exhibited marked pathological alterations, including severe hepatocellular ballooning, cytoplasmic lipid droplet accumulation, cellular swelling, and degeneration. Pyknotic nuclei with margination were observed in most hepatocytes, accompanied by cellular shrinkage and inflammatory infiltration. In the *Exercise plus* HFD group, these pathological changes were attenuated, and hepatic morphology was improved compared with the sedentary HFD group (Figure 4).

5. Discussion

The present study explored how moderate-intensity swimming exercise modulates high-fat diet-induced liver structural changes and metaflammation, with a focus on the role of the LOX-1 receptor. The findings indicate that regular aerobic exercise can reverse some manifestations of high-fat diet-induced MASLD, partly by improving histopathological appearance and metabolic profile and by attenuating the LOX-1/IL-6/NOx axis.

It is widely recognized that changes in dietary composition affect body mass and body weight by altering lipid profiles. Obesity, driven by a sedentary lifestyle and nutritional changes, is inversely associated with liver homeostasis, possibly through hepatocyte inflammation and nitrosative stress (13, 15, 16). The




Figure 4. Photomicrographs of liver with hematoxylin and eosin (H and E) staining. The images highlight different cellular conditions: the tip of the black arrow indicates shrinkage and necrotic hepatocytes, while the full black arrow points to ballooning and degenerated cells. The white arrow marks lipid droplets within the cytoplasm. Magnifications used are 20x and 40x, with scale bars measuring 20 μ m and 60 μ m respectively. The groups represented include Control (Cont), Exercise (Exe), High-Fat Diet (HFD) group, and High-Fat Diet combined with Exercise (HFD+Exe).

present findings indicate that high-fat diets lead to weight gain, whereas continuous aerobic activity prevents weight gain. Although the HFD increased cholesterol, LDL-C, and triglyceride levels, continuous swimming exercise specifically lowered triglycerides to levels comparable to those in the Control group. Notably, exercise did not significantly reduce serum cholesterol or LDL-C levels, suggesting a selective effect of exercise on triglyceride metabolism in this model.

In this study, chronic consumption of an HFD resulted in a significant increase in serum NOx levels. However, aerobic swimming exercise reduced NOx levels to those in the Control group, resulting in no pronounced difference in NOx levels between the *Exercise plus* HFD group and the Control group. Because measurement of total plasma NOx provides an integrated assessment of systemic nitric oxide production, elevated NOx levels in the context of MASLD have been attributed primarily to iNOS upregulation in inflamed hepatic tissue, contributing to nitrosative stress, protein nitration, and hepatocellular injury (8). The HFD produced a modest elevation in glucose levels that was not attenuated by the exercise intervention. Serum triglycerides were reduced following exercise, whereas cholesterol and LDL-C levels remained unchanged, suggesting a selective effect of exercise on triglyceride metabolism. This differential response may

be attributed to the structural properties of cholesterol, because skeletal muscle cannot use cholesterol as an energy substrate in the same manner as free fatty acids. Notably, although total cholesterol levels may remain unaltered, exercise has been associated with shifts in the distribution of LDL and HDL subfractions, potentially reflecting improved lipoprotein quality rather than quantity (17).

Dyslipidemia-induced lipotoxicity increases IL-6 release, which is linked to MASLD progression (18). IL-6 levels in the liver and blood are also higher in patients with NASH, and IL-6 may worsen hepatic inflammation and steatosis in MASLD (19). Kupffer cells may overproduce proinflammatory cytokines, a pathogenic characteristic of hepatic steatosis. Additionally, obesity recruits macrophages to the liver and changes their phenotype from M2 to M1 (20). Obesity-related hepatic inflammation leads to steatosis and liver lymphocyte infiltration by activating the IL-6 signaling pathway, which increases liver cell proliferation and hepatocyte degradation (21).

Immunohistochemical analysis revealed a substantial elevation in IL-6 and LOX-1 protein expression levels in the HFD group ($P < 0.001$). After 8 weeks of aerobic activity, both proteins showed lower expression levels relative to the HFD group but remained elevated compared with those in the Control

group ($P < 0.001$). These correlative findings demonstrate a strong association between LOX-1 expression and markers of MASLD severity. The HFD increased liver parenchymal volume, mean liver cell volume, and lipid accumulation, whereas exercise attenuated these morphological changes.

Consistent with previous reports, HFD feeding induced significant weight gain and hypercholesterolemia, accompanied by cytoplasmic lipid vacuolation in hepatocytes (13, 15, 22). In this study, the HFD increased total cholesterol, triglycerides, and LDL-C, whereas aerobic exercise selectively reduced triglycerides without affecting cholesterol or LDL-C levels. This selective effect may be attributed to obesity-related dyslipidemia and nitrosative stress, which have been shown to alter apolipoprotein B/ApoB100 synthesis and secretion, thereby reducing VLDL export and promoting triglyceride accumulation in hepatocytes (23). Stereological analysis revealed a decreased hepatocyte number with increased mean cell volume and a higher prevalence of swelling, cytoplasmic disorganization, and clear space formation resulting from cytoplasmic dilution and organelle loss (24, 25). Such degenerative lesions, which typically precede apoptosis, reflect the progressive nature of diet-induced hepatocellular injury (25). Furthermore, HFD-induced hepatic inflammation contributed to lobular architectural disruption through the accumulation of fat, protein, and fluid within the parenchyma and perivascular spaces, leading to focal necrosis (26). Subsequent inflammatory cell infiltration stimulated perisinusoidal and perivenular collagen deposition, which extended through the hepatic lobule and culminated in early bridging fibrosis (27). Ultimately, progressive fibrosis results in the replacement of functional parenchyma with connective tissue (25-27).

MASLD is intricately associated with hepatic metaflammation, and weight reduction is strongly linked to improvements in histological features of NASH (1-5). The present results demonstrated that chronic aerobic swimming exercise mitigated the effects of HFD by preventing weight gain and significantly reducing serum triglyceride levels. *Exercise* also modulated HFD-induced histological alterations, decreasing hepatic lipid accumulation and inflammatory cytokine expression. In MASLD, circulating leukocytes infiltrate the liver and produce inflammatory mediators. Activated immune cells and damaged hepatocytes release proinflammatory cytokines, perpetuating disease progression (25-27). Chronic inflammation represents a critical risk factor in the progression from uncomplicated steatosis to advanced NASH and fibrosis.

Exercise-mediated reductions in IL-6 and NOx levels in the present study suggest partial attenuation of this inflammatory cycle. These results support the concept that exercise improves MASLD-related histological changes and metabolic stress.

LOX-1 has been established as a downstream effector of endoplasmic reticulum stress signaling. Upregulation of LOX-1 contributes to MASLD progression by activating endoplasmic reticulum stress, and LOX-1 inhibition has been shown to alleviate endoplasmic reticulum stress (23, 28, 29). Moreover, proinflammatory cytokines, including IL-6, upregulate LOX-1 expression, thereby mediating inflammatory responses and apoptosis and underscoring the interplay between inflammation and endoplasmic reticulum stress (30). Supporting this, Deng et al. (31) demonstrated that chronic aerobic exercise attenuated HFD-induced metabolic dysregulation, insulin resistance, and hepatic fat accumulation in MASLD rats, concomitant with improved liver function markers.

The findings also demonstrate that exercise reduces serum triglycerides, nitric oxide, and hepatic IL-6 production. Consistent with these observations, Cheng-Maw et al. associated LOX-1 with portal venous inflammation in NASH, supporting the link between NAFLD, cholesterol accumulation, inflammation, and fibrosis (32). *Exercise* also reduces intrahepatic triglycerides and protects against lipotoxicity-induced obesity and steatohepatitis (33). A meta-analysis by Chen et al. confirmed that physical activity, including aerobic exercise, improves MASLD by reducing body fat percentage and waist-to-hip ratio (34). Mechanistically, regular exercise may attenuate chronic inflammation by promoting macrophage polarization from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype, thereby modulating cytokine production in adipose tissue and visceral fat (35). Furthermore, aerobic exercise enhances lipid oxidation and suppresses hepatic lipogenesis through inhibition of SCD-1 activity and activation of the AMPK pathway (36).

Following exercise, sustained AMPK activation in muscle, liver, and adipose tissue occurs in response to decreased energy charge, as indicated by an increased AMP/ATP ratio. In the liver, AMPK suppresses lipid synthesis through acetyl-CoA carboxylase inactivation, malonyl-CoA decarboxylase activation, and downregulation of lipogenic enzymes (36). Aerobic exercise further reduces hepatic fat through SREBP-1c downregulation, PPAR γ upregulation, and reduced nonesterified fatty acid delivery to the liver. These adaptations collectively reduce lipid accumulation and

inflammation, as evidenced by reduced tumor necrosis factor alpha, while enhancing energy expenditure and fat oxidation (37). Additionally, exercise elevates hepatocyte growth factor, a key promoter of hepatic regeneration, angiogenesis, and vascular remodeling, and exercise training supports liver regeneration, with effects modulated by training intensity and modality (38). The observed co-occurrence of attenuation of the LOX-1/IL-6/NOx axis in the exercise group further implies restoration of nitrosative and inflammatory balance.

This study offers the advantage of concurrently evaluating serum levels and immunohistochemical markers of oxidative stress and inflammation, enabling stronger conclusions regarding the modulation of inflammatory conditions and the improvement of liver-related morphological and biochemical parameters. The findings establish significant correlations between exercise-mediated LOX-1 downregulation and improved MASLD-related parameters, providing a foundation for future mechanistic investigations.

5.1. Study Limitations

The current investigation did not evaluate other inflammatory pathways that concurrently interact with LOX-1, such as TNF- α , the NLRP3 inflammasome, and other scavenger receptors, which may have enhanced the applicability of the findings. The observed reduction in total NOx following exercise could reflect decreased nitrosative stress, but the contribution of altered endothelial nitric oxide synthase-mediated protective signaling cannot be determined from these data. Most importantly, the correlative nature of the study design must be acknowledged. Although strong associations were observed between LOX-1 downregulation and MASLD improvement following exercise intervention, causal mechanisms remain to be established through pathway-specific inhibition or genetic manipulation studies.

5.2. Conclusions

In conclusion, obesity-induced steatohepatitis was characterized by elevated inflammatory cytokine levels, LOX-1 protein upregulation, and increased nitrosative stress. Regular aerobic exercise was associated with a predictable decrease in serum nitrosative stress and inflammatory cytokines in liver cells, consistent with the known anti-inflammatory and antistress therapeutic effects of regular aerobic exercise, rather than with reductions in cholesterol or LDL-C. Importantly, conclusions regarding improved liver function and metabolic improvement are based on indirect markers, including the lipid profile, NOx levels,

and histopathological analysis. The findings demonstrate that exercise is associated with improvements in morphological and biochemical parameters, but definitive conclusions regarding liver function improvement require direct enzymatic and functional assessment of hepatocellular injury markers, including ALT, AST, and insulin sensitivity indices. Given that oxidative stress and inflammation enhance LOX-1 expression and increased LOX-1 expression in turn exacerbates oxidative stress and inflammation, elevated LOX-1 expression appears to play a critical role in the progression of fatty liver and subsequent syndromes. Therefore, moderate-intensity swimming exercise appears to have a protective effect against hepatic steatosis and fatty liver, in part by reducing LOX-1 receptor expression, primarily through anti-inflammatory mechanisms.

Footnotes

AI Use Disclosure: The authors declare that no generative AI tools were used in the creation of this article.

Authors' Contribution: Study concept and design: All authors. Analysis and interpretation of data: S. R. and G. H. Critical revision of the manuscript for important intellectual content: N. H. and H. H. A. Z. All authors provided substantial feedback, reviewed and approved the final manuscript for publication.

Conflict of Interests Statement: The authors do not declare any conflicts of interests for this study.

Data Availability: The data presented in the study is available on request from the corresponding author during submission or after publication.

Ethical Approval: The study was approved by the Ethical Committee of the AJA University of Medical Sciences. (IR.AJAUMS.REC.1399.256) and all procedures were done according to the Declaration of Helsinki.

Funding/Support: No funding was received for this study.

References

1. Nakamura T, Masuda A, Nakano D, Amano K, Sano T, Nakano M, et al. Pathogenic mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma. *Cells*. 2025;14(6):428. [PubMed ID: 40136677]. [PubMed Central ID: PMC11941585]. <https://doi.org/10.3390/cells14060428>.
2. Kang M, Song J, Kang ES, Jang S, Kwak T, Kim Y, et al. Pathophysiology, development, and mortality of major non-communicable diseases in

- metabolic dysfunction-associated steatotic liver disease: A comprehensive review. *Int J Biol Sci.* 2025;**21**(13):5691-5703. [PubMed ID: 41079926]. [PubMed Central ID: PMC12509686]. <https://doi.org/10.7550/ijbs.117211>.
3. Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingham J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. *J Obes Metab Syndr.* 2023;**32**(3):197-213. [PubMed ID: 37700494]. [PubMed Central ID: PMC10583766]. <https://doi.org/10.7570/jomes23052>.
 4. Souto Maior MDRM, Ribeiro NDLI, Silva HWV, Lopes EP, Costa EC. Metabolic dysfunction-associated steatotic liver disease as a risk factor for chronic kidney disease: A narrative review. *Biomedicine.* 2025;**13**(9):2162. [PubMed ID: 41007724]. [PubMed Central ID: PMC12467166]. <https://doi.org/10.3390/biomedicine13092162>.
 5. Yang WQ, Xue LL, Wang JL. Metabolic dysfunction-associated steatotic liver disease: Mechanisms, metabolic reprogramming, and therapeutic insights. *World J Gastroenterol.* 2025;**31**(26):108814. [PubMed ID: 40678711]. [PubMed Central ID: PMC12264839]. <https://doi.org/10.3748/wjg.v31.i26.108814>.
 6. Solleiro-Villavicencio H, Viurcos-Sanabria R, Aguayo-Guerrero JA, Pineda-Pérez PF, Méndez-García LA. Inflammation: a key mechanism connecting metabolic-associated steatotic liver disease (MASLD) and systemic arterial hypertension (SAH). *Front Immunol.* 2025;**16**:1620585. [PubMed ID: 40977717]. [PubMed Central ID: PMC12446046]. <https://doi.org/10.3389/fimmu.2025.1620585>.
 7. Meyer M, Schwärzler J, Jukic A, Tilg H. Innate immunity and MASLD. *Biomolecules.* 2024;**14**(4):476. [PubMed ID: 38672492]. [PubMed Central ID: PMC11048298]. <https://doi.org/10.3390/biom14040476>.
 8. Cammisotto V, Valeriani E, Pignatelli P, Violi F. Nicotinamide adenine dinucleotide phosphate oxidases and metabolic dysfunction-associated steatotic liver disease. *Antioxidants.* 2025;**14**(1):83. [PubMed ID: 39857417]. [PubMed Central ID: PMC11763266]. <https://doi.org/10.3390/antiox14010083>.
 9. Riahy S, Mohammadi MT, Sobhani V, Abazadeh S. Chronic aerobic exercise decreases lectin-like low density lipoprotein (LOX-1) receptor expression in heart of diabetic rat. *Iran Biomed J.* 2016;**20**(1):26-32. [PubMed ID: 26432573]. [PubMed Central ID: PMC4689279]. <https://doi.org/10.7508/ibj.2016.01.004>.
 10. Hofnagel O, Luechtenborg B, Stolle K, Lorkowski S, Eschert H, Plenz G, et al. Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol.* 2004;**24**(10):1789-95. [PubMed ID: 15271788]. <https://doi.org/10.1161/01.ATV.0000140061.89096.2b>.
 11. Huang R, Yang Y, Zhou S, Zhu X, Hu C. LOX-1 gene knockout improves metabolic dysfunction-associated steatohepatitis in mice. *Journal of Central South University Medical Science.* 2025;**50**(11):2038-2050. [PubMed ID: 41656838]. [PubMed Central ID: PMC12949932]. <https://doi.org/10.11817/j.issn.1672-7347.2025.250194>.
 12. Klisic A, Tomašević R, Djuraskovic S, Mercantepe F, Ninic A. Biomarkers for early identification of metabolic dysfunction-associated steatotic liver disease (MASLD): a narrative review. *Arch Med Sci.* 2026;**22**(2):602-41. [PubMed ID: 42305303]. [PubMed Central ID: PMC13266762]. <https://doi.org/10.5114/aoms/219846>.
 13. Dongkun D, Qingfeng J, Chang L, Yunhua L, Jiaming S, Yufei L, et al. Comparative effects of different loads of aerobic exercise on lipid metabolism in MASLD rats: a perspective from the gut-liver axis. *Front Med.* 2025;**12**:1609751. [PubMed ID: 40735442]. [PubMed Central ID: PMC12305809]. <https://doi.org/10.3389/fmed.2025.1609751>.
 14. Hamedchaman N, Safarzade A, Hamidian G, Nasiri K. The effect of two types of aerobic training (continuous and interval) and vanadium-zinc complex supplementation on antioxidant genes expression in the testicular tissue of rats fed with fructose solution. *Sport Biosciences.* 2023;**15**(4):21-38. <https://doi.org/10.22059/jsb.2023.361255.1594>.
 15. Kolahdouzi S, Talebi-Garakani E, Hamidian G, Safarzade A. Exercise training prevents high-fat diet-induced adipose tissue remodeling by promoting capillary density and macrophage polarization. *Life Sci.* 2019;**220**:32-43. [PubMed ID: 30690082]. <https://doi.org/10.1016/j.lfs.2019.01.037>.
 16. Berdowska I, Matusiewicz M, Fecka I. A comprehensive review of metabolic dysfunction-associated steatotic liver disease: Its mechanistic development focusing on methylglyoxal and counterbalancing treatment strategies. *Int J Mol Sci.* 2025;**26**(6):2394. [PubMed ID: 40141037]. [PubMed Central ID: PMC11942149]. <https://doi.org/10.3390/ijms26062394>.
 17. Lonardo MS, Guida B, Cacciapuoti N, Chiurazzi M, Pacella D, Cataldi M. Evidence that skeletal muscles modulate HDL-cholesterol in metabolic healthy young adults. *Nutrients.* 2024;**16**(8):1110. [PubMed ID: 38674801]. [PubMed Central ID: PMC11054046]. <https://doi.org/10.3390/nu16081110>.
 18. Skuratovskaia D, Komar A, Vulf M, Quang HV, Shunkin E, Volkova L, et al. IL-6 reduces mitochondrial replication, and IL-6 receptors reduce chronic inflammation in NAFLD and type 2 diabetes. *Int J Mol Sci.* 2021;**22**(4):1774. [PubMed ID: 33579000]. [PubMed Central ID: PMC7916777]. <https://doi.org/10.3390/ijms22041774>.
 19. Vachliotis ID, Polyzos SA. The intriguing roles of cytokines in metabolic dysfunction-associated steatotic liver disease: a narrative review. *Curr Obes Rep.* 2025;**14**(1): 65. [PubMed ID: 40794228]. [PubMed Central ID: PMC12343754]. <https://doi.org/10.1007/s13679-025-00657-5>.
 20. Park SJ, Garcia Diaz J, Um E, Hahn YS. Major roles of Kupffer cells and macrophages in NAFLD development. *Front Endocrinol.* 2023;**14**:1150118. [PubMed ID: 37274349]. [PubMed Central ID: PMC10235620]. <https://doi.org/10.3389/fendo.2023.1150118>.
 21. Liu J, Wang T, Yang F, Pubu C. Advancements in the understanding of mechanisms of the IL-6 family in relation to metabolic-associated fatty liver disease. *Front Endocrinol.* 2025;**16**:1642436. [PubMed ID: 40969371]. [PubMed Central ID: PMC12440729]. <https://doi.org/10.3389/fendo.2025.1642436>.
 22. Oghbavi S, Shariati M. Aerobic exercise improves cardiac hypertrophy through the RAF/MEK/ERK complex pathway in the experimental model of obesity induced by a high fat/fructose diet in rats. *Jentashapir J Cell Mol Biol.* 2026;**17**(1): e164376. <https://doi.org/10.5812/jcmb-164376>.
 23. Conlon DM, Thomas T, Fedotova T, Hernandez-Ono A, Di Paolo G, Chan RB, et al. Inhibition of apolipoprotein B synthesis stimulates endoplasmic reticulum autophagy that prevents steatosis. *J Clin Invest.* 2016;**126**(10):3852-67. [PubMed ID: 27599291]. [PubMed Central ID: PMC5096813]. <https://doi.org/10.1172/JCI86028>.
 24. Chen K, Sun M, Wei N. *Adaptation and injury of cells and tissues.* Singapore: Springer Nature Singapore; 2024. p. 1-34. https://doi.org/10.1007/978-981-99-8445-9_1.
 25. Yang Y, Du X, Wang Q, Liu J, Zhang E, Sai L, et al. Mechanism of cell death induced by silica nanoparticles in hepatocyte cells is by apoptosis. *Int J Mol Med.* 2019;**44**(3):903-12. [PubMed ID: 31524225]. [PubMed Central ID: PMC6657974]. <https://doi.org/10.3892/ijmm.2019.4265>.
 26. Leiskau C, Baumann U. Structure, function, and repair of the liver. *Diseases of the Liver and Biliary System in Children.* 2017:1-17. <https://doi.org/10.1002/978119046936.ch1>.
 27. Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular mechanisms of liver fibrosis. *Front Pharmacol.* 2021;**12**: 671640. [PubMed ID: 34025430]. [PubMed Central ID: PMC8134740]. <https://doi.org/10.3389/fphar.2021.671640>.
 28. Venkatesan N, Doskey LC, Malhi H. The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis. *Am J Pathol.* 2023;**193**(12):1887-99. [PubMed ID: 37689385]. [PubMed Central ID: PMC10699131]. <https://doi.org/10.1016/j.ajpath.2023.08.007>.

29. Hong D, Li LF, Gao HC, Wang X, Li CC, Luo Y, et al. High-density lipoprotein prevents endoplasmic reticulum stress-induced downregulation of liver LOX-1 expression. *PLoS One*. 2015;**10**(4). e0124285. [PubMed ID: 25923692]. [PubMed Central ID: PMC4414515]. <https://doi.org/10.1371/journal.pone.0124285>.
30. Ding Z, Pothineni NVK, Goel A, Lüscher TF, Mehta JL. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. *Cardiovasc Res*. 2020;**116**(5):908-15. [PubMed ID: 31746997]. <https://doi.org/10.1093/cvr/cvz313>.
31. Deng D, Xu L, Liu Y, Li C, Jiang Q, Shi J, et al. HIIT versus MICT in MASLD: mechanisms mediated by gut-liver axis crosstalk, mitochondrial dynamics remodeling, and adipokine signaling attenuation. *Lipids Health Dis*. 2025;**24**(1). 144. [PubMed ID: 40241065]. [PubMed Central ID: PMC12004573]. <https://doi.org/10.1186/s12944-025-02565-y>.
32. Ho CM, Ho SL, Jeng YM, Lai YS, Chen YH, Lu SC, et al. Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease. *J Inflamm*. 2019;**16**(1). 7. [PubMed ID: 30983887]. [PubMed Central ID: PMC6444889]. <https://doi.org/10.1186/s12950-019-0211-5>.
33. Cui N, Li H, Dun Y, Ripley-Gonzalez JW, You B, Li D, et al. Exercise inhibits JNK pathway activation and lipotoxicity via macrophage migration inhibitory factor in nonalcoholic fatty liver disease. *Front Endocrinol*. 2022;**13**. 961231. [PubMed ID: 36147562]. [PubMed Central ID: PMC9485555]. <https://doi.org/10.3389/fendo.2022.961231>.
34. Chen J, Gong P, Xie J. Effects of exercise on body composition, fitness, and blood pressure in overweight or obese patients with MASLD: a systematic review and meta-analysis. *Dig Liver Dis*. 2025;**57**(11):2099-2108. [PubMed ID: 40973584]. <https://doi.org/10.1016/j.dld.2025.08.090>.
35. Kawanishi N, Yano H, Yokogawa Y, Suzuki K. Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice. *Exerc Immunol Rev*. 2010;**16**:105-118. [PubMed ID: 20839495].
36. McCaffrey JM, Ibdah JA. Effects of diet and exercise on mitochondrial health in metabolic dysfunction-associated steatotic liver disease (MASLD): Role of ceramides. *Nutrients*. 2025;**17**(18):2972. [PubMed ID: 41010498]. [PubMed Central ID: PMC12473040]. <https://doi.org/10.3390/nut17182972>.
37. Machado MV. Aerobic exercise in the management of metabolic dysfunction associated fatty liver disease. *Diabetes Metab Syndr Obes*. 2021;**Volume 14**:3627-3645. [PubMed ID: 34408459]. [PubMed Central ID: PMC8364841]. <https://doi.org/10.2147/DMSO.S304357>.
38. Sakaue A, Adachi H, Enomoto M, Fukami A, Nohara Y, Morikawa N, et al. Improvement of physical activity significantly reduced serum hepatocyte growth factor levels in a general population: 10 year prospective study. *Heart Vessels*. 2023;**38**(4):588-98. [PubMed ID: 36352166]. <https://doi.org/10.1007/s00380-022-02198-6>.